Skip to content

Released Nov 3, 2026, after the close

10-Q filed Nov 3, 2026, 34 days after period end · 0001193125-26-445534

Q3 2026 · 10-Q
Revenue$19.39M−0.9% vs Q3 2025−3.6% vs Q2 2026
Net Income$13.48MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted$0.03N/M vs Q3 2025N/M vs Q2 2026
Gross Profit$10,828,000+14.2%
Operating Income-$19,768,000N/M
Operating Cash Flowderived-$6,161,000N/M
Free Cash Flowderived-$6,161,000N/M
Margins · derived
Gross margin55.9%+7.4 pt vs Q3 2025
Operating margin-102.0%+66.5 pt vs Q3 2025
Net margin69.6%+247.0 pt vs Q3 2025

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$19.39M$19.55M$22.09M$25.37M
Net Income$13.48M-$34.69M-$26.94M-$21.00M
EPS Diluted$0.03-$0.09-$0.07-$0.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR